|
Consumers survey results of for 1 quarter of 2024 in category Gynecology, urology, nephrology / Medication for the treatment of menstrual cycle and PMS
 The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year. |
 |
I quarter (january—march) |
 |
II quarter (april—june) |
|
| 1. |
Ременс (Perrigo)
|
50.00% |
5 |
|
|
| 2. |
Гінекохеель (Heel)
|
25.00% |
2.50 |
|
|
| 2. |
Дисменорм (DHU) |
25.00% |
2.50 |
|
|
| 2. |
Мастодинон (Bionorica)
|
25.00% |
2.50 |
|
|
| –. |
Tazalok (Pro-Pharma)
|
0.00% |
0 |
 |
| –. |
Мулімен (Heel)
|
0.00% |
0 |
|
|
| –. |
Фемінал (Екомед) |
0.00% |
0 |
|
|
| –. |
Циклодінон (Bionorica)
|
0.00% |
0 |
|
| |
The annual ratings by results of Consumers survey calculated as average arithmetic mean rank, obtained in each of 4 quarters of year.
